Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

Variations in regulatory requirements across regions often create inefficiencies in drug development—for example, differences in manufacturing standards and stability testing protocols can lead ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...

we have the opportunity to significantly benefit patients and advance drug development. EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 earnings call, ...

Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...